Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements match on-label concepts (e.g., risks with premature discontinuation; general perioperative interruption timing language). However, multiple claims are either incomplete, not supported with the provided labeling excerpts, or reference non-label guideline organizations/outcomes without clear label support.
Category Scores
Accurate Statements
Stopping apixaban just before surgery may increase the risk of stroke or systemic embolism.
Supported by label concept in 5.1: premature discontinuation of any oral anticoagulant, including ELIQUIS, increases risk of thrombotic events; includes increased rate of stroke observed during transition from ELIQUIS to warfarin in AF trials.
According to the manufacturer, patients who need to undergo a surgical procedure should discuss the risks and benefits of continuing or stopping apixaban with their healthcare provider.
Partially supported: label counseling emphasizes not to discontinue ELIQUIS without talking to physician first (17). The provided excerpts do not explicitly say 'risks and benefits of continuing or stopping' but the general 'talk to physician' counsel is supported.
Unsupported Statements
Apixaban (Eliquis) is an anticoagulant medication used to prevent blood clots in patients with atrial fibrillation.
The provided FDA label excerpts for evaluation do not include the approved indication text in Section 1, so this specific indication wording is not supported by the supplied label content.
Apixaban (Eliquis) is an anticoagulant medication used to prevent blood clots in patients with deep vein thrombosis.
The provided FDA label excerpts do not include indication language for DVT (Section 1 not shown).
Apixaban (Eliquis) is an anticoagulant medication used to prevent blood clots in patients with pulmonary embolism.
The provided FDA label excerpts do not include indication language for pulmonary embolism (Section 1 not shown).
Apixaban should be discontinued at least 24 to 48 hours before elective surgery that has a moderate or high risk of bleeding.
Label excerpt states 'at least 48 hours prior' for moderate or high risk of unacceptable/clinically significant bleeding (2.4). The claim’s '24 to 48 hours' range for moderate/high bleeding is not supported by the provided label text.
The American College of Cardiology and the American Heart Association recommend continuing anticoagulation therapy during the perioperative period for low-risk patients.
Not supported by the provided FDA label excerpts; the label content shown does not mention these organizations’ recommendations.
The American College of Cardiology and the American Heart Association advise against continuing anticoagulation therapy during the perioperative period for patients at high risk of bleeding.
Not supported by the provided FDA label excerpts; the label content shown does not mention these organizations’ recommendations.
Patients who stopped apixaban for at least 24 hours before surgery had a higher risk of recurrent stroke or death compared to those who continued therapy.
The supplied label excerpts do not provide this specific comparative perioperative outcome statement for 'stopped for at least 24 hours' vs 'continued therapy.' The provided 5.1 excerpt discusses thrombotic risk during transition to warfarin in AF trials, not this perioperative comparison.
Contradictions
Low
AI Statement
Apixaban should be discontinued at least 24 to 48 hours before elective surgery that has a moderate or high risk of bleeding.
Label Reference
2.4 Temporary Interruption for Surgery and Other Interventions: 'ELIQUIS should be discontinued at least 48 hours prior to elective surgery... with a moderate or high risk of unacceptable or clinically significant bleeding.'
Important Omissions
For perioperative interruption, the label specifies different minimum discontinuation intervals depending on bleeding risk (48 hours for moderate/high; 24 hours for low/non-critical bleeding) and also notes that bridging during 24–48 hours after stopping is not generally required and that restarting should occur after adequate hemostasis is established (2.4).
Importance:
Moderate
The label includes additional counseling around neuraxial anesthesia/puncture risk and explicit symptom monitoring and timing instructions for catheter removal and next dose (5.3). None of the provided claims address this, which may be material depending on the user’s intended context (neuraxial procedures).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The perioperative timing claim for moderate/high bleeding is partially incorrect (suggests 24 hours may be sufficient), and several claims are unsupported by the provided label excerpts, which could lead to misinterpretation of perioperative management timing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Moderate/high bleeding discontinuation timing is misstated (label specifies at least 48 hours; claim states 24–48 hours). Several other claims (indications, guideline recommendations, specific comparative outcomes) are not supported by the provided label excerpts.
Suggested Improvement
Adjust perioperative timing wording to match 2.4 (use 'at least 48 hours' for moderate/high bleeding risk; 'at least 24 hours' for low risk). Remove or qualify non-label guideline and comparative outcome statements unless the label excerpts provided explicitly support them, and restrict indications to what is contained in Section 1 of the provided label text.